Colorectal Cancer Screening: “Blue March” Campaign Boosts Awareness in Brest, France

Brest, France – Health officials in the Finistère department of Brittany are intensifying efforts to boost colorectal cancer screening rates as part of the annual “Mars Bleu” (Blue March) campaign. This month-long initiative, mirroring the widely recognized “October Pink” for breast cancer awareness, focuses on prevention, early detection, and improved care for colorectal cancer, a leading cause of cancer-related deaths in France.

A collaborative meeting of key stakeholders – including representatives from the CPAM (primary health insurance fund), the Ligue contre le Cancer du Finistère (Finistère Cancer League), the CRCDC Bretagne (Brittany Regional Cancer Screening Center), and the ARS (Regional Health Agency) – was held in Brest on March 2, 2026, to strategize ways to increase participation in the national screening program. Colorectal cancer is particularly concerning because, whereas common, It’s also highly preventable through regular screening. The goal is to reach a 65% participation rate among individuals aged 50 to 74, a threshold considered essential for maximizing population-level protection.

The Importance of Early Detection

Colorectal cancer is the second most deadly cancer in France, responsible for over 17,000 deaths annually, according to data shared by the Assurance Maladie du Finistère in a recent LinkedIn post. Yet, when detected early, the prognosis is remarkably positive, with a 90% survival rate. This underscores the critical role of screening in reducing mortality.

Currently, screening rates in Finistère lag behind the national target. Between 2023 and 2024, less than one-third of eligible residents participated in the screening program. However, a concerted effort in 2025 saw an increase to 40% participation, a positive trend attributed to intensified mobilization efforts. “Thanks to a strengthened mobilization, we managed to increase this rate to 40% in 2025,” stated Yvon Foll, secretary-general of the Finistère branch of the Ligue contre le Cancer.

A Simple Test, Accessible to All

The screening process itself is straightforward and accessible. Free screening kits are readily available at pharmacies and involve a simple fecal immunochemical test (FIT), which detects hidden blood in stool. “A test is simple,” emphasized Maud Moreigne, risk management officer at the CPAM, highlighting the ease of participation. The campaign aims to inform and mobilize the population about the importance of early detection and prevention.

The CHU de Brest (University Hospital of Brest) is also playing a central role in the “Mars Bleu” initiative. On a dedicated day at the Institut de Cancérologie (Cancer Institute) within the hospital, a multidisciplinary team of healthcare professionals – including gastroenterologists, pathologists, molecular biologists, surgeons, geneticists, oncologists, and specialized nurses – will provide information, education, and support. The event will feature information booths, educational workshops, interactive discussions about care pathways, and brief presentations on the various stages of treatment.

Comprehensive Care Pathways at the CHU de Brest

The CHU de Brest emphasizes a holistic and personalized approach to colorectal cancer care. This includes a coordinated pathway encompassing gastroenterology, digestive surgery, medical oncology, and radiotherapy, alongside anatomical pathology, genetics, and molecular profiling. Patients benefit from integrated support services, such as dietetics, adapted physical activity, psychological support, socio-aesthetic care, and social assistance. Crucially, the CHU also strengthens coordination with local physicians and community healthcare structures to ensure seamless care transitions.

This integrated approach aims not only to improve patient outcomes but also to reduce health inequalities and ensure equitable access to care. The hospital’s commitment to a multidisciplinary approach reflects a growing understanding of the complex nature of cancer treatment and the importance of addressing the physical, emotional, and social needs of patients.

Targeted Outreach in Finistère

Recognizing that certain populations are less likely to participate in screening programs, the Assurance Maladie du Finistère and the CRCDC Bretagne have implemented a targeted outreach strategy. This “aller-vers” (going-towards) approach focuses on reaching vulnerable populations and underserved areas, including Morlaix, Carhaix, the Cap Sizun peninsula, Brest, Quimper, and Quimperlé.

In 2024, over 30,000 residents were contacted by phone, resulting in a 21% participation rate among those who engaged with the outreach services. Building on this success, the Assurance Maladie is continuing its proactive approach in 2025 with the “Mars Attack” campaign, collaborating with the Faculty of Medicine of Brest to further expand its reach. The objective is to achieve a screening participation rate of at least 45%.

Beyond direct outreach, the campaign encourages individuals to show their support by wearing a blue ribbon throughout March, a symbolic gesture raising awareness about colorectal cancer and the importance of screening. These ribbons are crafted by ASSOCIATION KAN AR MOR, a local organization dedicated to providing employment opportunities for individuals with disabilities, adding a social dimension to the health initiative.

Key Takeaways

• Colorectal cancer is a leading cause of cancer death in France, but early detection significantly improves survival rates.
• The “Mars Bleu” campaign aims to increase screening participation among individuals aged 50-74.
• Free and accessible screening kits are available at pharmacies.
• Targeted outreach programs are focusing on vulnerable populations in the Finistère department.
• A multidisciplinary approach to care, emphasizing personalized treatment and integrated support services, is central to the CHU de Brest’s strategy.

The ongoing efforts in Finistère, and across France during “Mars Bleu,” represent a crucial step towards reducing the burden of colorectal cancer and improving the health and well-being of the population. The next update on screening rates and campaign progress is expected in June 2026, following a comprehensive evaluation of the “Mars Bleu” initiative. We encourage readers to discuss colorectal cancer screening with their healthcare providers and to learn more about the program at the CHU de Brest website. Share this article with your network to assist spread awareness and encourage participation in this life-saving initiative.